- Home
- ASPS vs SKYE Comparison
ASPS vs SKYE Comparison
Compare ASPS & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPS
- SKYE
- Stock Information
- Founded
- ASPS 1999
- SKYE 2012
- Country
- ASPS Luxembourg
- SKYE United States
- Employees
- ASPS N/A
- SKYE N/A
- Industry
- ASPS Other Consumer Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ASPS Consumer Discretionary
- SKYE Health Care
- Exchange
- ASPS Nasdaq
- SKYE Nasdaq
- Market Cap
- ASPS 123.2M
- SKYE 121.8M
- IPO Year
- ASPS N/A
- SKYE N/A
- Fundamental
- Price
- ASPS $13.55
- SKYE $1.72
- Analyst Decision
- ASPS
- SKYE Strong Buy
- Analyst Count
- ASPS 0
- SKYE 5
- Target Price
- ASPS N/A
- SKYE $14.75
- AVG Volume (30 Days)
- ASPS 31.2K
- SKYE 1.6M
- Earning Date
- ASPS 10-23-2025
- SKYE 11-06-2025
- Dividend Yield
- ASPS N/A
- SKYE N/A
- EPS Growth
- ASPS N/A
- SKYE N/A
- EPS
- ASPS N/A
- SKYE N/A
- Revenue
- ASPS $168,271,000.00
- SKYE N/A
- Revenue This Year
- ASPS $38.29
- SKYE N/A
- Revenue Next Year
- ASPS N/A
- SKYE N/A
- P/E Ratio
- ASPS N/A
- SKYE N/A
- Revenue Growth
- ASPS 12.96
- SKYE N/A
- 52 Week Low
- ASPS $3.46
- SKYE $1.14
- 52 Week High
- ASPS $15.96
- SKYE $5.96
- Technical
- Relative Strength Index (RSI)
- ASPS 67.71
- SKYE 29.49
- Support Level
- ASPS $12.42
- SKYE $1.78
- Resistance Level
- ASPS $14.36
- SKYE $4.99
- Average True Range (ATR)
- ASPS 0.95
- SKYE 0.34
- MACD
- ASPS 0.23
- SKYE -0.29
- Stochastic Oscillator
- ASPS 77.25
- SKYE 1.20
About ASPS Altisource Portfolio Solutions S.A.
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.